News

Fierce Pharma17h
With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
Sanofi finds M&A fix for its multiple itches
The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...
Sanofi announces major purchase amid pledge to up U.S. investments
Global healthcare company Sanofi, headquartered in Paris, France, is announcing another pricey purchase in the U.S.
Fierce Biotech19h
Sanofi pays $15M for another STAT6 degrader from fruitful Nurix collab
Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...
STAT21h
Sanofi to buy Blueprint Medicines in deal worth more than $9 billion
Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline ...
Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment
Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...
Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials
Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...
Sanofi (SNY)’s MenQuadfi Becomes First MenACWY Vaccine Approved for Ages 6 Weeks and Up
The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...